Rab15 alternative splicing is altered in spheres of neuroblastoma cells

Oncology Reports

Volumn 27, Issue 6, 2012, Pages 2045-2049

  Pham, Thi Van Huyen ^a   Hartomo, Tri Budi ^a   Lee, Myeong Jin ^a   Hasegawa, Daiichiro ^b   Ishida, Toshiaki ^b   Kawasaki, Keiichiro ^b   Kosaka, Yoshiyuki ^b   Yamamoto, Tomoto ^a   Morikawa, Satoru ^a   Yamamoto, Nobuyuki ^a   Kubokawa, Ikuko ^a   Mori, Takeshi ^a   Yanai, Tomoko ^a   Hayakawa, Akira ^a   Takeshima, Yasuhiro ^a   Iijima, Kazumoto ^a   Matsuo, Masafumi ^c   Nishio, Hisahide ^a   Nishimura, Noriyuki ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Hyogo Children's Hospital   (Japan)

^c KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

Alternative splicing; Neuroblastoma; Rab15; Sphere; Tumor initiating cell

Indexed keywords

BIOLOGICAL MARKER; ISOPROTEIN; RAB PROTEIN; RAB15 PROTEIN; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; CHILD; CODON; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ALTERNATIVE SPLICING; BRAIN; HUMANS; MEMBRANE PROTEINS; NEUROBLASTOMA; PROTEIN ISOFORMS; RAB GTP-BINDING PROTEINS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84860735585     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1731     Document Type: Article

References (33)

1. Colon NC and Chung DH: Neuroblastoma. Adv Pediatr 58: 297-311, 2011.
2. Maris JM, Hogarty MD, Bagatell R and Cohn SL: Neuroblastoma. Lancet 369: 2106-2120, 2007. (Pubitemid 46935947)
3. Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216, 2003.
4. Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768, 2008.
5. Alison MR, Islam S and Wright NA: Stem cells in cancer: instigators and propagators? J Cell Sci 123: 2357-2368, 2010.
6. Bomken S, Fiser K, Heidenreich O and Vormoor J: Understanding the cancer stem cell. Br J Cancer 103: 439-445, 2010.
7. Maugeri-Saccà M, Vigneri P and De Maria R: Cancer stem cells and chemosensitivity. Clin Cancer Res 17: 4942-4947, 2011.
8. Hansford LM, McKee AE, Zhang L, et al: Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res 67: 11234-11243, 2007. (Pubitemid 350248549)
9. Takai Y, Sasaki T and Matozaki T: Small GTP-binding proteins. Physiol Rev 81: 153-208, 2001. (Pubitemid 32098004)
10. Nishimura N and Sasaki T: Rab family small G proteins in regulation of epithelial apical junctions. Front Biosci 14: 2115-2129, 2009.
11. Hutagalung AH and Novick PJ: Role of rab GTPases in membrane traffic and cell physiology. Physiol Rev 91: 119-149, 2011.
12. Chia WJ and Tang BL: Emerging roles for Rab family GTPases in human cancer. Biochim Biophys Acta 1795: 110-116, 2009.
13. Cheng K, Lahad J, Kuo W, et al: The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 10: 1251-1256, 2004. (Pubitemid 39540444)
14. Zhang J, Liu X, Datta A, et al: RCP is a human breast cancer-promoting gene with Ras-activating function. J Clin Invest 119: 2171-2183, 2009.
15. Akavia UD, Litvin O, Kim J, et al: An integrated approach to uncover drivers of cancer. Cell 143: 1005-1017, 2010.
16. Elferink LA, Anzai K and Scheller RH: rab15, a novel low molecular weight GTP-binding protein specifically expressed in rat brain. J Biol Chem 267: 5768-5775, 1992.
17. Zuk PA and Elferink LA: Rab15 differentially regulates early endocytic trafficking. J Biol Chem 275: 26754-26764, 2000.
18. Lai HC, Klisch TJ, Roberts R, Zoghbi HY and Johnson JE: In vivo neuronal subtype-specific targets of Atoh1 (Math1) in dorsal spinal cord. J Neurosci 31: 10859-10871, 2011.
19. Nishimura N, Pham TVH, Hartomo TB, et al: Rab15 expression correlates with retinoic acid-induced differentiation of neuroblastoma cells. Oncol Rep 26: 145-151, 2011.
20. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R and Montuenga LM: Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 8: 349-357, 2007. (Pubitemid 46464532)
21. David CJ and Manley JL: Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 24: 2343-2364, 2010.
22. Ward AJ and Cooper TA: The pathobiology of splicing. J Pathol 220: 152-163, 2010.
23. Nishimura N, Hartomo TB, Pham TVH, et al: Epigallocatechin gallate inhibits sphere formation of neuroblastoma BE(2)-C cells. Environ Health Prev Med: Sep 10, 2011 (Epub ahead of print).
24. McGlincy NJ and Smith CWJ: Alternative splicing resulting in nonsense-mediated mRNA decay: what is the meaning of nonsense? Trends Biochem Sci 33: 385-393, 2008.
25. Nicholson P, Yepiskoposyan H, Metze S, Zamudio Orozco R, Kleinschmidt N and Mühlemann O: Nonsense-mediated mRNA decay in human cells: mechanistic insights, functions beyond quality control and the double-life of NMD factors. Cell Mol Life Sci 67: 677-700, 2010.
26. Lukas J, Gao DQ, Keshmeshian M, et al: Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 61: 3212-3219, 2001. (Pubitemid 32691978)
27. Maxwell CA, Rasmussen E, Zhan F, et al: RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood 104: 1151-1158, 2004. (Pubitemid 39038037)
28. Adamia S, Reiman T, Crainie M, Mant MJ, Belch AR and Pilarski LM: Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma. Blood 105: 4836-4844, 2005. (Pubitemid 40807311)
29. Casciano I, Mazzocco K, Boni L, et al: Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 9: 246-251, 2002. (Pubitemid 34223868)
30. Lau LMS, Wolter JK, Lau JTML, et al: Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene 28: 2024-2033, 2009.
31. Flora A, Klisch TJ, Schuster G and Zoghbi HY: Deletion of Atoh1 disrupts Sonic Hedgehog signaling in the developing cerebellum and prevents medulloblastoma. Science 326: 1424-1427, 2009.
32. Shi F, Cheng Yf, Wang XL and Edge ASB: Beta-catenin up-regulates Atoh1 expression in neural progenitor cells by interaction with an Atoh1 3′ enhancer. J Biol Chem 285: 392-400, 2010.
33. Weinstein JL, Katzenstein HM and Cohn SL: Advances in the diagnosis and treatment of neuroblastoma. Oncologist 8: 278-292, 2003. (Pubitemid 36648814)